Obinutuzumab patent expiry?

Obinutuzumab (brand Gazyva, Roche/Genentech) is a cancer monoclonal antibody. However, “patent expiry” depends on the specific patent(s) and territory (US vs. EU vs. UK, etc.), and whether you mean first generic entry, marketing exclusivity, or last patent expiration.

Quick reality check

As of my last update (mid‑2024), obinutuzumab’s core patents were in the past decade and the product has been off‑patent in many markets for some time, but exact “expiry” dates vary by country and by which patent family you track (composition of matter vs. formulation vs. method-of-use, plus patent term extensions).

To give you an accurate expiry date, I need:

1. Country/region (e.g., US, EU, UK, Canada)
2. What you mean by expiry:
   • Last patent expiration (full freedom-to-operate in that region), or
   • First generic/biosimilar launch date, or
   • Data/marketing exclusivity end
3. If you’re tracking a specific filing: WO/EP/US patent number (if you have it)

If you tell me the jurisdiction, I can look up/structure the likely timeline

Reply with “US” or “EU/UK” (or another country) and what “expiry” means for you, and I’ll map out the relevant patent/exclusivity timeline as precisely as possible.